Filing Analysis
Regulation FD Disclosure
Filed Apr 10, 2026
LOW
Lantern Pharma Inc. conducted a live demonstration and presentation of its 'withZeta.ai' platform, a multi-agentic AI co-scientist designed for rare cancer drug discovery and clinical trial design. The presentation detailed the platform's commercial architecture, revenue strategy, and growth roadmap.
Red Flags
- The company notes a risk that they may not be able to secure sufficient future funding to support the withZeta.ai platform.
Key Facts
- The demonstration occurred on April 9, 2026, focusing on the withZeta.ai platform.
- The platform is intended to assist in rare cancer drug discovery, development, and clinical trial design.
- The company's near-term revenue strategy for the platform includes software licensing and subscription models.
- A replay of the demonstration was made available via a Zoom recording link.
- The filing includes Exhibit 99.1, which is the presentation used during the demonstration.
Regulation FD Disclosure
Filed Mar 30, 2026
LOW
Lantern Pharma Inc. announced its financial and operating results for the fiscal year and fourth quarter ended December 31, 2025. The filing includes a press release and a presentation for a scheduled conference call and live webinar to discuss these results.
Key Facts
- Financial results for the fiscal year and fourth quarter ended December 31, 2025, were announced on March 30, 2026.
- The company furnished a press release as Exhibit 99.1 under Item 2.02.
- A presentation for a conference call and live webinar was furnished as Exhibit 99.2 under Item 7.01.
- The filing was signed by David R. Margrave, Chief Financial Officer.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.